- Home
- MCRB vs JLS Comparison
MCRB vs JLS Comparison
Compare MCRB & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- JLS
- Stock Information
- Founded
- MCRB 2010
- JLS 2009
- Country
- MCRB United States
- JLS United States
- Employees
- MCRB N/A
- JLS N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- JLS Investment Managers
- Sector
- MCRB Health Care
- JLS Finance
- Exchange
- MCRB Nasdaq
- JLS Nasdaq
- Market Cap
- MCRB 103.7M
- JLS 97.1M
- IPO Year
- MCRB 2015
- JLS N/A
- Fundamental
- Price
- MCRB $12.09
- JLS $18.99
- Analyst Decision
- MCRB Hold
- JLS
- Analyst Count
- MCRB 4
- JLS 0
- Target Price
- MCRB $73.67
- JLS N/A
- AVG Volume (30 Days)
- MCRB 107.4K
- JLS 26.6K
- Earning Date
- MCRB 08-12-2025
- JLS 01-01-0001
- Dividend Yield
- MCRB N/A
- JLS 9.33%
- EPS Growth
- MCRB N/A
- JLS N/A
- EPS
- MCRB 8.98
- JLS N/A
- Revenue
- MCRB N/A
- JLS N/A
- Revenue This Year
- MCRB N/A
- JLS N/A
- Revenue Next Year
- MCRB N/A
- JLS N/A
- P/E Ratio
- MCRB $1.42
- JLS N/A
- Revenue Growth
- MCRB N/A
- JLS N/A
- 52 Week Low
- MCRB $6.53
- JLS $15.48
- 52 Week High
- MCRB $30.60
- JLS $17.97
- Technical
- Relative Strength Index (RSI)
- MCRB 66.74
- JLS 77.25
- Support Level
- MCRB $10.67
- JLS $18.75
- Resistance Level
- MCRB $12.84
- JLS $19.05
- Average True Range (ATR)
- MCRB 1.09
- JLS 0.18
- MACD
- MCRB 0.34
- JLS 0.03
- Stochastic Oscillator
- MCRB 85.98
- JLS 92.86
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.